Literature DB >> 12449717

Early detection and successful treatment of drug-induced pneumonitis with corticosteroids.

Rachel Ash-Bernal1, Ilene Browner, Rodrigo Erlich.   

Abstract

A 69-year-old patient with non-small cell lung cancer developed pneumonitis with the use of the chemotherapeutic drugs gemcitabine, paclitaxel, and vinorelbine. He developed progressively worsening dyspnea, fevers, chills, and night sweats three weeks after initiation of chemotherapy treatment with no improvement with antibiotics. Bronchoscopic lung biopsy and endotracheal cultures were negative. Four weeks after the onset of symptoms, chest computed tomography scan showed a ground glass appearance of the lung parenchyma bilaterally consistent with pneumonitis. Gemcitabine is a nucleoside analog with activity against solid tumors, including breast and non-small cell lung cancers. Pneumonitis is a rare and potentially deadly complication of gemcitabine. Early treatment with corticosteroids leads to a complete resolution of this patients pneumonitis. Gemcitabine was discontinued and his chemotherapeutic regimen was changed to include paclitaxel, vinorelbine, and topotecan with no recurrence of pneumonitis. Pneumonitis should be included in the differential diagnosis of dyspnea in patients undergoing gemcitabine-based chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12449717     DOI: 10.1081/cnv-120005899

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  2 in total

1.  Radiologic evaluation of pulmonary injury following carmustine- and cyclophosphamide-based preparative regimen for autologous peripheral blood stem cell transplantation in children.

Authors:  Yu Jin Kim; Woo Sun Kim; Young Hun Choi; Jung-Eun Cheon; Jung Yoon Choi; Hyoung Jin Kang; Ji-Eun Park; Young Jin Ryu; In-One Kim
Journal:  Pediatr Radiol       Date:  2018-08-18

2.  Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma.

Authors:  Flávio Henrique Ferreira Galvão; José Osmar Medina Pestana; Vera Luiza Capelozzi
Journal:  Cancer Chemother Pharmacol       Date:  2010-02       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.